On July 23, an FDA advisory panel voted eight to six, with one abstention, to recommend that compounding pharmacies be allowed to produce BPC-157, TB-500, and two other injectable peptides that the agency had barred under the previous administration. The vote followed a February appearance in which Health and Human Services Secretary Robert F. Kennedy Jr. told Joe Rogan, "I'm a big fan of peptides; I've used them myself and used them with really good effect," broadcast to millions of listeners from Rogan's Texas studio (The Independent). Three weeks later, the regulatory machinery Kennedy oversees moved to loosen restrictions on the very compounds he had endorsed on air.
The recommendation is not binding, and the FDA has not approved these peptides as safe or effective for any medical use. What the vote does is signal that the agency may place the compounds in Category 1 of its bulks list, permitting compounding pharmacies to formulate them into custom prescriptions. For the wellness influencers, clinic operators, and podcasters who have spent years marketing these amino-acid chains as injury healers, collagen builders, and gut-repair agents, the vote represents the closest thing to institutional validation they have received. GQ described the aftermath bluntly: "the injectable drugs are only going to get more popular."
From Podcast to Pharmacy
Figure 1: Regulatory framework and distribution compliance overview for FDA Panel Endorses Peptides Promoted by Rogan and RFK Jr., Bending Regulation Toward Podca.
The path from Rogan's microphone to an FDA hearing room ran through a specific marketing term: the wolverine stack peptide, a combination of BPC-157 and TB-500 that Rogan has credited with helping him recover from a muscle injury. The name, borrowed from a comic-book character known for rapid healing, gave listeners a memorable brand for compounds that otherwise carry alphanumeric labels and no approved indications. WIRED reported that the advisory panel's recommendation explicitly included "the 'Wolverine stack' touted by Joe Rogan and other influencers."
Rogan was not the only voice amplifying these products. Andrew Huberman has discussed peptide injections for injury recovery on his podcast. Gary Brecka, a biohacker who sells peptide vials through his website and supports Kennedy's "Make America Healthy Again" agenda, appeared alongside the secretary in promotional settings. Brigham Buhler, a wellness clinic owner whose client roster includes Rogan and other celebrities, testified in favor of legal compounding, arguing it would steer Americans away from unvetted imports from China and India (Los Angeles Times). Dr. Alex Tatum, who has appeared on high-profile wellness programs including "Diary of a CEO," is part of the same cohort of practitioners positioning peptide protocols as consumer health products, though no FDA hearing transcript in the available records attributes specific efficacy claims to him under oath.
The cultural pipeline operates in both English and Spanish-language wellness spaces, where the same stack names and before-and-after testimonials circulate across TikTok, Instagram Reels, and podcast clips. The compounds are legally sold online labeled "research use only" and "not for human consumption," yet their marketing imagery and influencer testimonials heavily imply therapeutic use, according to WIRED's reporting. China and India remain major suppliers, and WIRED noted that some crypto-funded fentanyl labs have shifted production toward peptides.
The Vote and Its Conflicts
The eight-to-six margin was narrow, and the panel's composition drew scrutiny. WIRED reported that the advisory committee "includes several members tied to peptide-related businesses and telehealth clinics." The New York Times identified six committee members who sell peptides, including self-described longevity physicians who market the compounds for overall health and specific diseases, and whose clinics also offer ozone therapy and energy healing. Fortune reported that FDA scientists found only rat data on the seven peptides under review.
Dr. Elizabeth Rebello of the University of Texas MD Anderson Center voiced the dissenting position during the hearing: "I'm concerned we're responding to a market-induced demand rather than a decision based in solid science." Panel members with academic backgrounds rather than peptide-industry ties mostly voted against the substances, according to U.S. News reporting on the session.
FDA staff scientists argued against broadening access throughout the all-day hearing, citing the agency's prior warnings about injection risks including infection, allergic reactions, and contamination. Under the Biden administration, the FDA classified 19 peptides as unsafe and barred compounding pharmacies from producing them. Kennedy has characterized those restrictions as "illegal" suppression, framing the reclassification as correcting an overreach rather than evaluating new evidence.
The Guardian reported that Mark Mikhail, CEO of one of two main compounding pharmacies in the peptide market, was appointed to the pro-Kennedy MAHA PAC, where he advocated lifting the regulations that kept pharmacies from producing these compounds. "Follow the money," a critic identified only as Madison told the Guardian. "You're definitely seeing these strategic alliances."
What Compounding Changes for Consumers
A Category 1 listing would not make BPC-157 an approved drug. It would allow licensed compounding pharmacies to prepare individualized prescriptions containing the peptide, subject to FDA inspection. In practice, the distinction between compounding and approved manufacture matters: compounded products bypass the clinical-trial requirements that govern FDA-approved drugs like insulin or GLP-1 agonists. Peptide therapy as marketed by wellness clinics already operates in a regulatory gap, and the vote would widen that gap rather than close it.
The stakes of unregulated access are not hypothetical. The Guardian reported that in early July, a 27-year-old New York woman died after a botched injection of what was supposed to be an anti-aging peptide, administered by a proprietor not licensed to practice in New York. The peptide in question had been legal to compound. A hidden market of unlicensed practitioners administering these products has flourished alongside the legal one.
The FDA told the Guardian it is "considering the pharmacy compounding advisory committee's recommendations" and will make a final decision after consulting with the United States Pharmacopeia and reviewing other available information. No timeline has been announced. The votes are advisory, and the agency has periodically overridden its outside experts in the past.
Kennedy's stated position leaves little ambiguity about which direction he wants the final rule to go. On a podcast last year with Brecka, he said the FDA should "just do the science" on peptides and unproven stem-cell treatments "but not tell people, and not tell physicians, what they can and cannot prescribe." Whether the agency's career scientists, who spent the July hearing presenting the absence of human safety data, will carry weight in that final determination remains the open question the vote did not resolve.
